跳至主要内容
临床试验/CTRI/2023/12/060847
CTRI/2023/12/060847Not Applicable3 期

Exploring the Impact of Combined Oral Contraceptives: Estetrol/Drospirenone vs. Ethinyl Estradiol/Drospirenone on Glucose Tolerance in Polycystic Ovarian Syndrome- An Open-label Crossover Study - NI

Faculty of Medicine Research Scholarship, Prince of Songkhla university0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
Not Applicable
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • A diagnosis of PCOS according to the modified 2003 Rotterdam diagnostic criteria

排除标准

  • -Patients with contraindications to the use of COCs, according to MEC categories 3 and 4.
  • -Pregnancy
  • -History of hysterectomy or bilateral salpingo-oophorectomy
  • -Previous chemotherapy or radiation therapy
  • -Recent use of hormonal drugs within the past 2 months
  • -Use of medications that reduce the effectiveness of oral contraceptives (such as Rifampicin, Rifabutin, Barbiturates, Carbamazepine, Lamotrigine, Oxcarbazepine, Phenytoin, Primidone, and Topiramate)
  • -Abnormalities of the pituitary gland (including hyperprolactinemia and adenoma)
  • -Other ovarian disorders such as premature ovarian failure
  • -Abnormal thyroid function
  • -Patients who have undergone gastric bypass surgery for obesity
  • -Patients receiving insulin sensitizer drugs such as metformin
  • -Patients receiving treatment for dyslipidemia
  • -Patients have the intention to reduce weight
  • -Patients receiving treatment with GLP-1 receptor agonist

研究者

发起方
Faculty of Medicine Research Scholarship, Prince of Songkhla university

相似试验